CTI Laboratory Services Supports all Facets of Drug Development, Excels in Rare Disease Research

CTI supports all facets of clinical research and drug development throughout the world, with an emphasis on rare disease research. CTI recently acquired Dynakin to support its efforts in Europe, the Middle East, and Africa. Its expertise in real world data (RWD) and real world evidence (RWE) allows for critical insights into regenerative and rare diseases.

“CTI began work in laboratory services decades ago in complicated transplant trials, and has since grown their expertise around the intricacies of assays and methodologies in lab services supporting rare disease and regenerative medicine trials. This includes novel assay development and validation, sophisticated modeling to guide dosing decisions, and long term sample storage in a biorepository.” Learn more here.

(Source: CTI, 8/3/21)